Twist Bioscience (TWST) Stock Price

Twist Bioscience Price

NASDAQ·CLOSED
118.57USD-6.72 (-5.51 %)
Market closed

Over the last 9 years Twist Bioscience grew revenue by 84.5% annually, reaching 376.57 M USD. For Twist Bioscience, the net margin of -20.6% is up versus -115.3% a few years ago. The consensus 12-month price target for Twist Bioscience is 51.00 USD, about 57.0% below where the stock trades today. Of 17 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 391% above its 52-week low.

Twist Bioscience stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Twist Bioscience over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Twist Bioscience stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Twist Bioscience's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Twist Bioscience Stock Price History
DateTwist Bioscience Price
8/14/2026118.57 USD
8/13/2026125.29 USD
8/12/2026123.56 USD
8/10/2026123.65 USD
8/7/2026115.67 USD
8/6/2026109.08 USD
8/5/2026112.54 USD
8/4/2026100.73 USD
8/3/2026101.06 USD
7/31/202691.55 USD
7/30/202691.33 USD
7/29/202683.91 USD
7/27/202685.70 USD
7/23/202692.44 USD
7/22/202694.21 USD
7/21/202695.86 USD
7/20/202687.45 USD
7/17/202693.85 USD
7/16/202691.23 USD
7/15/202692.61 USD
7/14/202692.53 USD
7/13/202691.78 USD
7/10/202690.64 USD
7/9/202693.67 USD
7/8/202690.77 USD
7/7/202691.03 USD
7/6/2026101.22 USD
7/2/202699.24 USD
7/1/2026102.25 USD
6/30/2026102.88 USD
6/29/202698.71 USD
6/26/202699.84 USD
6/25/202696.65 USD
6/24/202691.35 USD
6/23/202685.00 USD
6/22/202685.15 USD
6/18/202686.02 USD
6/17/202688.13 USD
6/16/202685.72 USD
6/15/202681.05 USD
6/12/202676.78 USD
6/11/202669.38 USD
6/10/202670.54 USD
6/9/202670.06 USD
6/8/202670.04 USD
6/5/202671.31 USD
6/4/202679.21 USD
6/3/202671.21 USD
6/2/202668.92 USD
6/1/202667.40 USD
5/29/202669.79 USD
5/28/202669.00 USD
5/27/202664.40 USD
5/26/202663.89 USD
5/22/202660.30 USD
5/21/202653.67 USD
5/20/202652.32 USD
5/19/202649.50 USD
5/18/202649.79 USD
5/15/202649.17 USD
5/14/202652.95 USD
5/13/202654.39 USD
5/12/202655.95 USD
5/11/202656.21 USD
5/8/202656.85 USD
5/7/202658.54 USD
5/6/202659.53 USD
5/5/202656.70 USD
5/4/202656.19 USD
5/1/202660.40 USD
4/30/202658.45 USD
4/29/202656.70 USD
4/28/202659.15 USD
4/27/202661.00 USD
4/24/202660.94 USD
4/23/202658.85 USD
4/22/202663.20 USD
4/21/202662.61 USD
4/20/202661.88 USD
4/17/202659.81 USD
4/16/202656.23 USD
4/15/202657.62 USD
4/14/202657.41 USD
4/13/202650.38 USD
4/10/202647.91 USD
4/9/202648.84 USD
4/8/202651.17 USD
4/7/202650.12 USD
4/6/202651.18 USD
4/2/202650.21 USD
4/1/202649.54 USD
3/31/202647.52 USD
3/30/202643.26 USD
3/27/202644.53 USD
3/26/202646.75 USD
3/25/202648.64 USD
3/24/202647.49 USD
3/23/202644.50 USD
3/20/202642.07 USD
3/19/202644.80 USD
3/18/202644.46 USD
3/17/202647.28 USD
3/16/202645.01 USD
3/13/202643.28 USD
3/12/202643.02 USD
3/11/202646.86 USD
3/10/202645.40 USD
3/9/202648.33 USD
3/6/202646.94 USD
3/5/202648.66 USD
3/4/202648.06 USD
3/3/202646.65 USD
3/2/202645.89 USD
2/27/202646.92 USD
2/26/202648.71 USD
2/25/202649.58 USD
2/24/202648.54 USD
2/23/202648.09 USD
2/20/202648.59 USD
2/19/202652.49 USD
2/18/202654.92 USD
2/17/202652.88 USD
2/13/202649.11 USD
2/12/202647.66 USD
2/11/202649.64 USD
2/10/202649.06 USD
2/9/202647.47 USD
2/6/202649.24 USD
2/5/202647.10 USD
2/4/202648.12 USD
2/3/202646.32 USD
2/2/202646.81 USD
1/30/202641.07 USD
1/29/202641.58 USD
1/28/202642.01 USD
1/27/202642.60 USD
1/26/202642.46 USD
1/23/202642.94 USD
1/22/202645.15 USD
1/21/202643.65 USD
1/20/202641.65 USD
1/16/202641.41 USD
1/15/202641.27 USD
1/14/202640.03 USD
1/13/202640.22 USD
1/12/202638.04 USD
1/9/202635.32 USD
1/8/202634.74 USD
1/7/202636.55 USD
1/6/202636.87 USD
1/5/202634.34 USD
1/2/202632.39 USD
12/31/202531.72 USD
12/30/202532.15 USD
12/29/202532.85 USD
12/26/202533.05 USD
12/24/202533.58 USD
12/23/202533.84 USD
12/22/202535.06 USD
12/19/202532.51 USD
12/18/202531.92 USD
12/17/202532.13 USD
12/16/202531.13 USD
12/15/202531.07 USD
12/12/202530.93 USD
12/11/202532.12 USD
12/10/202532.78 USD
12/9/202531.58 USD
12/8/202532.22 USD
12/5/202532.30 USD
12/4/202532.81 USD
12/3/202531.17 USD
12/2/202529.70 USD
12/1/202529.86 USD
11/28/202532.01 USD
11/26/202531.70 USD
11/25/202531.11 USD
11/24/202529.33 USD
11/21/202528.56 USD
11/20/202526.07 USD
11/19/202525.45 USD
11/18/202526.00 USD
11/17/202526.46 USD
11/14/202526.87 USD
11/13/202529.90 USD
11/12/202531.87 USD
11/11/202531.32 USD
11/10/202530.96 USD
11/7/202530.27 USD
11/6/202530.63 USD
11/5/202531.52 USD
11/4/202530.06 USD
11/3/202531.57 USD
10/31/202532.89 USD
10/30/202531.17 USD
10/29/202532.21 USD
10/28/202533.57 USD
10/27/202534.18 USD
10/24/202534.11 USD
10/23/202531.83 USD
10/22/202531.06 USD
10/21/202533.39 USD
10/20/202532.74 USD
10/17/202528.16 USD
10/16/202530.75 USD
10/15/202532.04 USD
10/14/202530.55 USD
10/13/202530.14 USD
10/10/202531.19 USD
10/9/202531.89 USD
10/8/202532.79 USD
10/7/202531.12 USD
10/6/202531.85 USD
10/3/202531.07 USD
10/2/202530.68 USD
10/1/202529.26 USD
9/30/202528.14 USD
9/29/202527.00 USD
9/26/202526.91 USD
9/25/202526.75 USD
9/24/202527.02 USD
9/23/202527.64 USD
9/22/202527.81 USD
9/19/202527.89 USD
9/18/202527.95 USD
9/17/202526.97 USD
9/16/202527.08 USD
9/15/202525.72 USD
9/12/202525.31 USD
9/11/202525.61 USD
9/10/202524.16 USD
9/9/202525.09 USD
9/8/202526.25 USD
9/5/202525.76 USD
9/4/202525.63 USD
9/3/202526.00 USD
9/2/202526.24 USD
8/29/202526.97 USD
8/28/202526.59 USD
8/27/202527.19 USD
8/26/202527.72 USD
8/25/202527.39 USD
8/22/202528.59 USD
8/21/202526.47 USD
8/20/202526.45 USD
8/19/202527.58 USD
8/18/202528.02 USD
Access this data via the Eulerpool API
Get Free API Key

Twist Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
245.10 M USD
-217.16 M USD
-204.62 M USD
Jan 1, 2024
312.95 M USD
-220.83 M USD
-208.73 M USD
Jan 1, 2025
376.57 M USD
-136.26 M USD
-77.67 M USD
Jan 1, 2026 (e)
456.29 M USD
-330.28 M USD
-35.88 M USD
Jan 1, 2027 (e)
539.22 M USD
-387.80 M USD
-37.88 M USD
Jan 1, 2028 (e)
613.16 M USD
-453.67 M USD
-47.55 M USD
Jan 1, 2029 (e)
733.75 M USD
-542.90 M USD
21.53 M USD
Jan 1, 2030 (e)
868.50 M USD
-642.60 M USD
82.54 M USD

Twist Bioscience Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 5:18 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e
2.0010.0025.0054.0090.00132.00203.00245.00312.00376.00456.00539.00613.00733.00868.00
–400.00150.00116.0066.6746.6753.7920.6927.3520.5121.2818.2013.7319.5818.42
-350.00-130.00-24.0011.1131.1138.6441.3836.3342.6350.8050.8050.8050.8050.8050.80
-7.00-13.00-6.006.0028.0051.0084.0089.00133.00191.00231.64273.80311.39372.35440.93
-43.00-58.00-70.00-108.00-140.00-152.00-249.00-217.00-220.00-136.00-330.00-387.00-453.00-542.00-642.00
-2,150.00-580.00-280.00-200.00-155.56-115.15-122.66-88.57-70.51-36.17-72.37-71.80-73.90-73.94-73.96
-44.00-59.00-71.00-107.00-139.00-152.00-217.00-204.00-208.00-77.00-35.00-37.00-47.0021.0082.00
–34.0920.3450.7029.919.3542.76-5.991.96-62.98-54.555.7127.03-144.68290.48
2.0018.7827.2532.9846.0049.9156.4457.5059.1661.0861.0861.0861.0861.0861.08
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Twist Bioscience generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Twist Bioscience retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Twist Bioscience's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Twist Bioscience has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Twist Bioscience's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Twist Bioscience stock margins

The Twist Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Twist Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Twist Bioscience.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
39.19 %
-115.73 %
-115.26 %
Jan 1, 2022
41.40 %
-122.38 %
-107.07 %
Jan 1, 2023
36.61 %
-88.60 %
-83.48 %
Jan 1, 2024
42.61 %
-70.57 %
-66.70 %
Jan 1, 2025
50.72 %
-36.18 %
-20.63 %
Jan 1, 2026 (e)
50.72 %
-72.38 %
-7.86 %
Jan 1, 2027 (e)
50.72 %
-71.92 %
-7.02 %
Jan 1, 2028 (e)
50.72 %
-73.99 %
-7.75 %

Twist Bioscience Stock Revenue, EBIT, Earnings per Share

The Twist Bioscience earnings per share therefore indicates how much revenue Twist Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.64 USD
-3.06 USD
-3.05 USD
Jan 1, 2022
3.61 USD
-4.41 USD
-3.86 USD
Jan 1, 2023
4.26 USD
-3.78 USD
-3.56 USD
Jan 1, 2024
5.29 USD
-3.73 USD
-3.53 USD
Jan 1, 2025
6.17 USD
-2.23 USD
-1.27 USD
Jan 1, 2026 (e)
7.63 USD
-5.41 USD
-0.60 USD
Jan 1, 2027 (e)
9.02 USD
-6.35 USD
-0.63 USD
Jan 1, 2028 (e)
10.25 USD
-7.43 USD
-0.80 USD

Twist Bioscience business model & stock analysis

Twist Bioscience Corp is a company specializing in the production and applications of synthetic DNA. It was founded in 2013 and is based in San Francisco, California, USA. The company utilizes proprietary technologies to cost-effectively produce high-quality and high-quantity synthetic DNA. The company operates in three business areas: DNA synthesis, biopharmaceuticals, and data storage. The DNA synthesis division is the core of the company and involves the production of synthetic DNA for applications in various industries, including medicine, agricultural science, biotechnology, plastic engineering, and others. The company manufactures customized DNA synthesis products tailored to the needs of its customers, allowing them to accelerate and optimize their research and development projects. Twist Bioscience has also developed a proprietary technology called "Twist Biosensor" that enables rapid and cost-effective analysis of genetic variations. The biopharmaceutical division focuses on the development of therapeutics and diagnostics based on synthetic DNA. Twist Bioscience develops antibodies and proteins that can be used in cancer and immunotherapy, as well as diagnostics. In the data storage field, Twist Bioscience develops solutions for storing large amounts of data on DNA. This technology utilizes the dense and stable structure of DNA to securely and reliably store data in the long term. Twist Bioscience's DNA synthesis products are utilized by researchers, companies, and public institutions in various industries. Customers value not only the wide product portfolio but also the high quality and precision of the products, as well as the speed of order processing. The company operates a number of manufacturing facilities near its customers in Europe and Asia to ensure fast and efficient delivery of its products. This allows Twist Bioscience to have a strong position in the global market. In recent years, the company has achieved significant milestones. In 2018, Twist Bioscience went public and raised a total of $70 million through its IPO. The company has also established partnerships with various other companies and institutions to develop new applications and products. Overall, Twist Bioscience is a growing company specializing in the production and applications of synthetic DNA. With its wide range of high-quality and customized DNA synthesis products, as well as its innovative solutions in the biopharmaceutical and data storage sectors, the company has established a strong market position.

Twist Bioscience SWOT Analysis

Strengths

1. Leading provider of synthetic DNA and gene synthesis services in the market.

2. Strong reputation for high-quality products and customer satisfaction.

3. Broad and diverse customer base across various industries.

4. Extensive knowledge and expertise in synthetic biology and genomics.

Weaknesses

1. Reliance on third-party suppliers for raw materials may affect supply chain stability.

2. Limited presence in international markets, potentially missing out on global opportunities.

3. Vulnerability to changes in government regulations regarding genetic engineering.

Opportunities

1. Increasing demand for synthetic DNA and gene synthesis in various industries.

2. Emerging markets and untapped potential in international expansion.

3. Advancements in biotechnology and genomics present new opportunities for innovation.

Threats

1. Intense competition from other synthetic biology companies in the market.

2. Economic downturns and global market uncertainties may impact customer spending.

3. Legal and ethical concerns surrounding genetic engineering may restrict business growth.

Twist Bioscience Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Twist Bioscience Employees
Details
Date
Twist Bioscience Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Twist Bioscience Segments

Twist Bioscience Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • Max

Synthetic Genes
NGS Tools
Oligo Pools
DNA Libraries
Details
Date
Synthetic Genes
NGS Tools
Oligo Pools
DNA Libraries
Jan 1, 2019
26.71 M USD
21.04 M USD
4.59 M USD
2.04 M USD

Twist Bioscience Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • Max

Industrial Chemicals
Health Care
Academic Research
Agricultural
Details
Date
Industrial Chemicals
Health Care
Academic Research
Agricultural
Jan 1, 2019
21.93 M USD
17.42 M USD
13.84 M USD
1.20 M USD

Twist Bioscience Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
EMEA
Asia Pacific
North America
Details
Date
United States
EMEA
Asia Pacific
North America
Jan 1, 2019
35.94 M USD
14.69 M USD
2.76 M USD
996,000.00 USD

Twist Bioscience Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Twist Bioscience historical P/E ratio, EBIT multiple, and P/S ratio

Twist Bioscience annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Twist Bioscience shares outstanding

The number of shares of Twist Bioscience was 61.08 M in 2025. This indicates how many shares Twist Bioscience is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
49.91 M Stocks
Jan 1, 2022
56.44 M Stocks
Jan 1, 2023
57.50 M Stocks
Jan 1, 2024
59.16 M Stocks
Jan 1, 2025
61.08 M Stocks
Jan 1, 2026 (e)
61.08 M Stocks
Jan 1, 2027 (e)
61.08 M Stocks
Jan 1, 2028 (e)
61.08 M Stocks

Current Twist Bioscience forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
25.00 %
Buy
82.35 % (14)
Hold
17.65 % (3)
Sell
0.00 % (0)
12M Price Target
51.00
Last Price
118.57
Currency
USD
12M Return Potential
-56.99 %
LTM Return
0 %

Twist Bioscience Analyst Rating Actions

DateFirmActionRatingReliability
7/14/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
7/6/2026
Evercore ISI Group
Evercore ISI Group
DowngradeOutperformIn Line62
6/29/2026
Guggenheim
Guggenheim
MaintainedBuy30
6/24/2026
Barclays
Barclays
MaintainedOverweight33
6/15/2026
TD Cowen
TD Cowen
MaintainedBuy60
6/11/2026
Piper Sandler
Piper Sandler
MaintainedOverweight51
5/5/2026
Leerink Partners
Leerink Partners
UpgradeMarket PerformOutperform–
5/5/2026
Guggenheim
Guggenheim
MaintainedBuy30
5/5/2026
Barclays
Barclays
MaintainedOverweight33
5/5/2026
Baird
Baird
MaintainedOutperform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Twist Bioscience Earnings Calls

2025

Twist Bioscience Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/3/2026-0.50USD-116.77 MUSD-2026 Q3
5/4/2026-0.49USD-109.81 MUSD-2026 Q2
2/2/2026-0.44USD-102.82 MUSD-2026 Q1
11/14/2025-0.44USD-99.26 MUSD-2025 Q4
11/18/2024-0.72USD-83.85 MUSD-2024 Q4
5/3/2024-0.78USD-71.08 MUSD-2024 Q2
2/1/2024-0.79USD-68.79 MUSD-2024 Q1
11/16/2023-1.16USD-78.07 MUSD-2023 Q4
8/3/2023-1.16USD-71.47 MUSD-2023 Q3
5/3/2023-1.23USD-63.63 MUSD-2023 Q2

EESG©

Eulerpool ESG Scorecard© for the Twist Bioscience stock

33/100
19
Environment
51
Social
28
Governance
E

Environment

20
Scope 1 - Direct Emissions6.27
Scope 2 - Indirect emissions from purchased energy14,315
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions14,321.27
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees42
Percentage of women in management—
Percentage of Asian employees34
Share of Asian management38
Percentage of Hispanic/Latino employees11
Hispano/Latino Management share10
Percentage of Black employees2
Black Management Share1
Percentage of white employees44
White Management Share40
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Twist Bioscience shareholder structure

% Name
10.64703%
ARTISAN PARTNERS LIMITED PARTNERSHIP
ARTISAN PARTNERS LIMITED PARTNERSHIP
10.60516%
ARK INVESTMENT MANAGEMENT LLC
ARK INVESTMENT MANAGEMENT LLC
9.28699%
BLACKROCK, INC.
BLACKROCK, INC.
8.99967%
EDGEPOINT INVESTMENT GROUP INC.
EDGEPOINT INVESTMENT GROUP INC.
8.81106%
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
6.13744%
STATE STREET CORP
STATE STREET CORP
...

Twist Bioscience Beneficial Ownership Filings (SEC 13D/G)

Free Float
95.9%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.63%
FMR LLC
FMR LLC
SEC ↗
10.63%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
10.35%
ARK Investment Management LLC
ARK Investment Management LLC
SEC ↗
10.20%
Robert Nelsen
Robert Nelsen
SEC ↗
10.20%
Keith Crandell
Keith Crandell
SEC ↗
10.20%
Clinton Bybee
Clinton Bybee
SEC ↗
10.20%
ARCH Venture Partners VII, L.P.
ARCH Venture Partners VII, L.P.
SEC ↗
10.20%
ARCH Venture Partners VIII, LLC
ARCH Venture Partners VIII, LLC
SEC ↗
10.20%
ARCH Venture Fund VIII Overage, L.P.
ARCH Venture Fund VIII Overage, L.P.
SEC ↗
10.10%
Artisan Partners Asset Management Inc.
Artisan Partners Asset Management Inc.
SEC ↗

Twist Bioscience Executives and Management Board

13 members · avg. age 59 · 31 % women

EL

Dr. Emily Leproust (52)

Chairman of the Board, Chief Executive Officer · since 2013

7.62 M USD

Management

AL

Mr. Adam Laponis (48)

Chief Financial Officer

5.01 M USD
PF

Mr. Patrick Finn (53)

President, Chief Operating Officer

3.85 M USD
PG

Ms. Paula Green (57)

Senior Vice President - Human Resources

2.01 M USD
DC

Mr. Dennis Cho (54)

Chief Legal Officer and Corporate Secretary

1.80 M USD
RW

Mr. Robert Werner (51)

Chief Accounting Officer, Vice President

–

Board of Directors

RC

Mr. Robert Chess (68)

Lead Independent Director

307,481.00 USD
NC

Mr. Nelson Chan (64)

Independent Director

284,981.00 USD
JJ

Mr. Jan Johannessen (68)

Independent Director

284,981.00 USD
RR

Mr. Robert Ragusa (65)

Independent Director

277,481.00 USD
MS

Dr. Melissa Starovasnik (59)

Independent Director

277,481.00 USD
KC

Mr. Keith Crandell (64)

Independent Director

272,481.00 USD

Frequently asked questions about Twist Bioscience

The business model of Twist Bioscience Corp revolves around synthetic biology and DNA synthesis. Twist Bioscience is a leading company specializing in the production and commercialization of synthetic DNA constructs. The company offers comprehensive solutions that enable researchers and industries to leverage the power of DNA synthesis for various applications, including precision medicine, agricultural biotechnology, and industrial chemicals. Twist Bioscience employs a high-throughput silicon-based DNA synthesis platform, empowering scientists to rapidly and cost-effectively create customized genes, antibodies, and other DNA-based products. With its innovative technology and extensive product portfolio, Twist Bioscience Corp aims to drive discovery, accelerate development, and address real-world challenges through advanced synthetic biology solutions.

Twist Bioscience Corp is primarily active in the biotechnology and life sciences industries.

The main competitors of Twist Bioscience Corp in the market are GenScript Biotech Corporation, Integrated DNA Technologies, and Eurofins Genomics.

Twist Bioscience Corp, a leading company in synthetic biology, was founded in 2013. It aims to revolutionize the way DNA is being synthesized by providing high-quality, custom DNA at scale. The company's innovative silicon platform enables the efficient production of DNA, RNA, and proteins. With a vast portfolio of products and services, Twist Bioscience Corp caters to various industries such as healthcare, pharmaceuticals, agriculture, and industrial chemicals. By leveraging its proprietary technology, the company has secured partnerships with renowned organizations worldwide. Today, Twist Bioscience Corp continues to push the boundaries of synthetic biology, promoting advancements in fields ranging from drug discovery to data storage.

Twist Bioscience Corp has achieved several significant milestones. The company successfully launched the Twist Bioscience Tool Suite, a powerful set of DNA writing tools enabling researchers to generate synthetic DNA at scale. Additionally, Twist Bioscience Corp collaborated with Microsoft and researchers to store and retrieve digital data using DNA. The company also introduced the Twist Bioscience NGS Target Enrichment Solution, revolutionizing next-generation sequencing applications. Furthermore, Twist Bioscience Corp expanded its product portfolio by launching the Twist Human Core Exome Kit, facilitating the comprehensive analysis of genetic variations. These milestones showcase the company's commitment to innovation and its role in advancing genetic research and development.

Twist Bioscience Corp is primarily present in the United States, with headquarters located in South San Francisco, California. The company also has a strong presence in Europe, specifically in the United Kingdom and Germany. Additionally, Twist Bioscience Corp has expanded its reach into the Asia-Pacific region, with operations in Singapore and China. With a focus on synthetic biology and DNA synthesis, Twist Bioscience Corp is at the forefront of genetic engineering advancements. The company's innovative solutions and partnerships have allowed it to establish a global presence in the biotechnology industry.

Twist Bioscience Corp represents innovative values and a strong corporate philosophy. With a focus on synthetic biology, the company aims to accelerate breakthroughs in areas like healthcare, sustainability, and data storage. Twist Bioscience believes in the power of DNA synthesis technology to enable a wide range of applications that can transform multiple industries. By providing high-quality, custom DNA synthesis solutions, the company strives to empower researchers, scientists, and industry partners to create novel solutions and drive scientific advancements. Leveraging their expertise in DNA synthesis and bioinformatics, Twist Bioscience Corp is committed to fostering a more sustainable, healthier, and data-driven future.

Analysts currently set an average price target of 48.35 USD for the Twist Bioscience stock (median: 51.00 USD), implying -59.2 % versus the latest price. The consensus is based on 17 analyst ratings.

Twist Bioscience Analyst Price Targets 2026

17 analysts currently rate the Twist Bioscience stock: 14 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Twist Bioscience to generate revenue of 456.29 M USD and earnings per share of -0.59 USD.

Twist Bioscience Analyst Price Targets 2026

Converted at the current exchange rate, the Twist Bioscience share trades at 102.46 EUR (118.57 USD).

The Twist Bioscience share (TWST) is listed on 4 stock exchanges, including: NASDAQ (TWST), Frankfurt (0ME.F), München (0ME.MU), Düsseldorf (0ME.DU).

Twist Bioscience Corp was founded in 2013 in San Francisco and specializes in the production of synthetic DNA strands used in research and biotechnology. Their business model is based on their proprietary synthesis technology, which allows them to produce large quantities of high-quality, customized DNA quickly and cost-effectively. The company offers its products and services in four main areas: 1. DNA synthesis: Twist Bioscience offers a variety of DNA synthesis products used by researchers, companies, and government agencies. They produce synthetic DNA strands in various formats and sizes, including DNA primers, oligonucleotides, gene fragments, and complete genes. 2. Data and information analysis: To effectively work with Twist Bioscience, it is important for customers to analyze and understand the data from their DNA samples. Therefore, the company has developed a platform for data and information analysis that allows customers to process their genetic data quickly and easily. 3. Bio-products: Twist Bioscience has developed a variety of bio-products based on their DNA technology. These products include antibodies, RNA probes, protein A colloids, and other biological reagents. 4. DNA storage: In addition to their DNA production activity, Twist Bioscience has also developed a technology for storing data on synthetic DNA. This method of data storage is designed to enable long-term, secure, and cost-effective storage of large amounts of data. Twist Bioscience has customers worldwide in fields such as biotechnology, pharmaceuticals, diagnostics, agriculture, and the research community overall. It also works closely with government agencies to create solutions for bio-scientific critical applications and meet the growing demands of the market. Through its DNA synthesis products and information analysis, bio-products, and innovative DNA storage technology, Twist Bioscience remains at the forefront of genomics and biotechnology. The company has received several patents and awards, including the "Best Workplace" award from the San Francisco Business Times and the Silicon Valley Business Journal in 2018. Its expanding presence in Asian markets and successful expansion even during the COVID-19 pandemic period are among its key success factors.

The expected revenue of Twist Bioscience is 456.29 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Twist Bioscience is -35.88 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Twist Bioscience is currently -201.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Twist Bioscience stock.

The price-to-sales ratio (P/S) of Twist Bioscience is currently 15.87. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Twist Bioscience stock.

The Eulerpool Quality Score for Twist Bioscience is 3/10.

The ISIN of Twist Bioscience is US90184D1000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Twist Bioscience is A2N7L2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Twist Bioscience is TWST. The ticker symbol is used to trade Twist Bioscience shares on the stock exchange.

Twist Bioscience paid dividends every year for the past 0 years.

Twist Bioscience is assigned to the 'Health' sector.

The dividends of Twist Bioscience are distributed in USD.

All fundamentals and in-depth analysis of Twist Bioscience

Our stock analysis for Twist Bioscience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Twist Bioscience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Twist Bioscience Stock
Twist Bioscience Revenue→
Twist Bioscience Stock
Twist Bioscience Net Income→
Twist Bioscience Stock
Twist Bioscience P/E→
Twist Bioscience Stock
Twist Bioscience P/S→
Twist Bioscience Stock
Twist Bioscience EBIT→
Twist Bioscience Stock
Twist Bioscience Dividend→
Twist Bioscience Stock
Twist Bioscience Directors Dealings→
Twist Bioscience Stock
Twist Bioscience Stocks→
Twist Bioscience Stock
Twist Bioscience Market capitalization→
Twist Bioscience Stock
Twist Bioscience Debt→
Twist Bioscience Stock
Twist Bioscience Liabilities→
Twist Bioscience Stock
Twist Bioscience Equity→
Twist Bioscience Stock
Twist Bioscience AAQS→
Twist Bioscience Stock
Twist Bioscience Employees→
Twist Bioscience Stock
Twist Bioscience ROE→
Twist Bioscience Stock
Twist Bioscience ROA→
Twist Bioscience Stock
Twist Bioscience ROCE→
Twist Bioscience Stock
Twist Bioscience News→
Twist Bioscience Stock
Twist Bioscience Analyst Price Targets→

Health Stocks

Tyche IndustriesTwi BiotechnologyTycoon Group HoldingsTwareat Medical Care Company SCJSCTYK MedicinesTvardi TherapeuticsTyra BiosciencesTuoxin Pharmaceutical Group CoU-ARK Technology CoTuHURA BiosciencesU-Neuron BiomedicalTTY Biopharm CoAll Stocks A–Z →